Effects of antipsychotic treatment on membrane phospholipid metabolism in schizophrenia

Journal of Neurology

Volumn 248, Issue 9, 2001, Pages 1081-1091

  Schmitt, A ^a   Maras, A ^a   Petroianu, G ^b   Braus, D F ^a   Scheuer, L ^a   Gattaz, W F ^c  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^b Institute of Pharmacology and Toxicology   (Germany)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antipsychotic treatment; Lysophosphatidylcholine; Phospholipids; Platelets; Schizophrenia

Indexed keywords

LYSOPHOSPHATIDYLCHOLINE; MEMBRANE PHOSPHOLIPID; NEUROLEPTIC AGENT; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; HALOPERIDOL; PHOSPHOLIPID;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG WITHDRAWAL; FEMALE; FRONTAL LOBE; HUMAN; HUMAN CELL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; SCHIZOPHRENIA; BLOOD; CELL MEMBRANE; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY; THROMBOCYTE;

ADULT; ANTIPSYCHOTIC AGENTS; BLOOD PLATELETS; CELL MEMBRANE; FEMALE; HALOPERIDOL; HUMANS; MALE; PHOSPHOLIPIDS; SCHIZOPHRENIA;

EID: 0034869802     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Phosphorus assay in column chromatography
2. The WHO psychological impairment rating schedule (WHO/PIRS). II. Impairment in schizophrenics in cross-sectional and longitudinal perspective - The Mannheim experience in two independent samples
3. A rapid method of total lipid extraction and purification
4. Phospholipids and prostaglandins in schizophrenia
5. Phospholipase A2: Function and pharmacological regulation
6. 31Phosphorus magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia
7. Study of chronic schizophrenics using 31P magnetic resonance chemical shift imaging
8. Phosphorus magnetic resonance spectroscopy in schizophrenia: Correlation between membrane phospholipid metabolism in the temporal lobe and positive symptoms
9. Haloperidol improves membrane phospholipid abnormalities in temporal lobes of schizophrenic patients
10. Increased plasma phospholipase A2 activity in schizophrenic patients: Reduction after neuroleptic therapy
11. Increased serum phospholipase A2 activity in schizophrenia: A replication study
12. Possible involvement of phospholipase A2 in the pathogenesis of schizophrenia
13. Accelerated breakdown of membrane phospholipids in schizophrenia-implications for the hypofrontality hypothesis
14. Increased platelet phospholipase A2 activity in schizophrenia
15. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia
16. Phospholipases: In search of a genetic base of schizophrenia
17. In vivo 31P-NMR spectroscopy of the frontal lobe metabolism in neuroleptic naive first episode psychoses
18. Magnetic resonance spectroscopy in schizophrenia: Methodological issues and findings, part II
19. Method for determination of different phospholipids by high performance thin-layer chromatography
20. The use of the brief psychiatric rating scale (BPRS) by Overall and Gorham in the diagnosis of acute paranoid psychoses: Evaluation of a german translation of the BPRS
21. PLA2 activity in schizophrenics and other psychiatric patients
22. Increased platelet membrane lysophosphatidylcholine in schizophrenia
23. Optical shape analysis in stirred and unstirred human platelet suspensions. A comparison of aggregometric and stopped-flow turbidimetric measurements
24. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients
25. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics
26. 31P nuclear magnetic resonance spectroscopy: Neurodevelopment and schizophrenia
27. Increased phospholipid breakdown in schizophrenia
28. Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia
29. Blood platelets in psychopharmacological research
30. Phospholipid and prostaglandin hypothesis of schizophrenia
31. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy
32. Improved separation of phospholipids in thin-layer chromatography
33. Effect of neuroleptics on phospholipase A2 activity in the brain of rats
34. Increase of phosphodiesters during neuroleptic treatment of schizophrenics: A longitudinal 31P-magnetic resonance spectroscopic study
35. Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls
36. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients